MedPath

Gmax Biopharm Australia Pty Ltd.

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106

Phase 1
Completed
Conditions
Overweight and Obesity
Interventions
Drug: GMA106 Injection
Drug: GMA106 Matching Placebo
First Posted Date
2021-09-23
Last Posted Date
2024-01-30
Lead Sponsor
Gmax Biopharm Australia Pty Ltd.
Target Recruit Count
73
Registration Number
NCT05054530
Locations
🇦🇺

CMAX Clinical Research, Adelaide, South Australia, Australia

A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers

Phase 1
Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: GMA301 Injection
Other: GMA301 Placebo Injection
First Posted Date
2020-08-10
Last Posted Date
2021-09-01
Lead Sponsor
Gmax Biopharm Australia Pty Ltd.
Target Recruit Count
16
Registration Number
NCT04505137
Locations
🇦🇺

CMAX Clinical Research, Adelaide, South Australia, Australia

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.